Acrivon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	25.32	25.21	21.08	8.71	2.47	1.3
Research & Development	69.09	63.99	46.02	23.95	13.72	1.87
Operating Expenses	94.41	89.2	67.1	32.66	16.18	3.17
Operating Income	-94.41	-89.2	-67.1	-32.66	-16.18	-3.17
Interest & Investment Income	8.79	9.2	7.04	-	-	0.03
Other Non Operating Income (Expenses)	-4.12	-4.34	-3.65	0.79	-0.06	-0.07
EBT Excluding Unusual Items	-89.74	-84.33	-63.71	-31.87	-16.24	-3.21
Gain (Loss) on Sale of Investments	3.78	3.78	3.32	0.7	-	-
Other Unusual Items	-	-	-	-	-	-2.1
Pretax Income	-85.96	-80.56	-60.39	-31.17	-16.24	-5.31
Net Income	-85.96	-80.56	-60.39	-31.17	-16.24	-5.31
Net Income to Common	-85.96	-80.56	-60.39	-31.17	-16.24	-5.31
Shares Outstanding (Basic)	38	34	22	4	2	1
Shares Outstanding (Diluted)	38	34	22	4	2	1
Shares Change (YoY)	48.59%	53.05%	435.63%	136.43%	21.70%	-
EPS (Basic)	-2.24	-2.38	-2.74	-7.56	-9.32	-3.70
EPS (Diluted)	-2.24	-2.38	-2.74	-7.56	-9.32	-3.70
Free Cash Flow	-73.2	-68.44	-43.93	-32.28	-14.22	-2.82
Free Cash Flow Per Share	-1.91	-2.02	-1.99	-7.83	-8.16	-1.97
EBITDA	-93.21	-88.19	-66.57	-32.29	-16.15	-3.16
D&A For EBITDA	1.2	1.01	0.54	0.36	0.04	0.01
EBIT	-94.41	-89.2	-67.1	-32.66	-16.18	-3.17

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q